Asthma
Conditions
Brief summary
In asthma, breathing in an allergen, such as house dust mite induces inflammation in the airways. This process appears to involve an interaction between two different sorts of blood cells, platelets and white blood cells via a receptor called the P2Y12 receptor. The purpose of this study is to determine whether the drug clopidogrel which blocks the P2Y12 receptor on platelets, reduces inflammation following breathing in house dust mite in people with mild asthma.
Interventions
DRUGClopidogrel
Clopidogrel 75mg daily for 7 days
DRUGPlacebo
Matched placebo
Sponsors
University of Southampton
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of asthma * Step one of treatment by GINA (2006) guidelines * baseline FEV1 \>80% predicted
Exclusion criteria
* current smoker * ex smoker who quit \<1 year prior to study and pack history \>10 pack years * current use of aspirin or other anticoagulant medication * Diagnosis or documented history of bronchopulmonary aspergillosis or uncontrolled infections * Any clinically significant cardiopulmonary abnormalities not related to pre-existing asthma * Past or present tuberculosis, systemic lupus erythematosis or multiple sclerosis * Any clinically significant neurological, renal, endocrine, gastrointestinal, hepatic or haematological abnormalities uncontrolled with standard treatment * History of psychiatric, medical or surgical disorders that may interfere with study * Clinical history suggestive of respiratory infection in month preceding study * Alcohol or recreational drug abuse * Diagnosis of immunodeficiency requiring treatment * Treatment with immunomodulators (inhaled corticosteroids in two months or oral corticosteroids in six months prior to study) * Ongoing allergen desensitisation therapy * Regular use of sedatives, hypnotics, tranquillisers * Positive hepatitis viral antigens or antibodies * Blood donation within 3 months of the study * Live immunisation \<4 wks prior to study * Inability to understand directions for study assessment * Inability to be contacted in case of emergency * Participation in another study at the same time or within a prior 3-month period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in sputum eosinophils following allergen challenge in the presence and absence of clopiodgorel | 8 days |
Secondary
| Measure | Time frame |
|---|---|
| Change in urine fibrin degradation products and leukotriene E4 following allergen challenge in the presence and absence of clopidogrel | 8 days |
| Change in sputum P-selectin concentration following allergen challenge in the presence and absence of clopidogrel | 8 days |
| Provoking concentration of methacholine inducing 20% fall in forced expiratory volume in 1 second | 8 days |
| Change in peripheral blood eosinophil and platelet counts following allergen challenge in the presence and absence of clopidogrel | 8 days |
| Change in sputum tissue factor inhibitor concentration following allergen challenge in the presence and absence of clopidogrel | 8 days |
| Change in sputum thrombin activatable finbrinolysis inhibitor concentration following allergen challenge in the presence and absence of clopidogrel | 8 days |
| Change in sputum tissue factor concentration following allergen challenge in the presence and absence of clopidogrel | 8 days |
Countries
United Kingdom
Outcome results
None listed